Biogen, Eisai Report Long-Term Data Showing Patients Choose to Stay on Lecanemab Treatment
MT Newswires Live
Mar 21
Biogen (BIIB) and Eisai said Friday that an analysis of real-world data showed that most patients choose to continue receiving lecanemab after the initial 18 months of treatment.
The companies said 94% of patients who completed 18 months of lecanemab treatment in a phase 3 study enrolled in the subsequent long-term extension study.
In the extension study, patients continue to benefit from four years of lecanemab treatment, showing a reduction in cognitive decline, compared with the natural course of Alzheimer's disease, according to a statement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.